[go: up one dir, main page]

PE20010761A1 - Cristales del acido (e)-4-[4-(5-metil-2-fenil-4-oxazolilmetoxi)benziloxiimino]-4-fenilbutirico - Google Patents

Cristales del acido (e)-4-[4-(5-metil-2-fenil-4-oxazolilmetoxi)benziloxiimino]-4-fenilbutirico

Info

Publication number
PE20010761A1
PE20010761A1 PE2000001148A PE0011482000A PE20010761A1 PE 20010761 A1 PE20010761 A1 PE 20010761A1 PE 2000001148 A PE2000001148 A PE 2000001148A PE 0011482000 A PE0011482000 A PE 0011482000A PE 20010761 A1 PE20010761 A1 PE 20010761A1
Authority
PE
Peru
Prior art keywords
crystals
oxazolylmetoxy
benzyloximine
phenyl
methyl
Prior art date
Application number
PE2000001148A
Other languages
English (en)
Inventor
Yu Momose
Hiroshi Imoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20010761A1 publication Critical patent/PE20010761A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A CRISTALES DE ACIDO (E)-4-[4-(5-METIL-2-FENIL-4-OXAZOLILMETOXI)BENZILOXIIMINO]-4-FENILBUTIRICO, CON LA CONDICION QUE LOS CRISTALES CON PUNTO DE FUSION DE 126°C A 127°C QUEDEN EXCLUIDOS; CARACTERIZADOS POR TENER UN PUNTO DE FUSION ENTRE 136°C Y 139°C; UN PATRON DE DIFRACCION DE RAYOS X. EL COMPUESTO REGULA LA FUNCION DEL RECEPTOR RELACIONADO CON LOS RETINOIDES; RECEPTORES ACTIVADOS CON EL PROLIFERADOR DE LOS PEROXISOMAS Y PUEDE SER UTIL PARA EL TRATAMIENTO DE LA DIABETES MELLITUS, HIPERLIPEMIA, DISMINUCION EN LA TOLERANCIA DE LA GLUCOSA, ENFERMEDADES INFLAMATORIAS, ARTERIOESCLEROSIS, AUMENTA LA SENSIBILIDAD A LA INSULINA
PE2000001148A 1999-10-29 2000-10-26 Cristales del acido (e)-4-[4-(5-metil-2-fenil-4-oxazolilmetoxi)benziloxiimino]-4-fenilbutirico PE20010761A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP30834699 1999-10-29

Publications (1)

Publication Number Publication Date
PE20010761A1 true PE20010761A1 (es) 2001-08-01

Family

ID=17979966

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001148A PE20010761A1 (es) 1999-10-29 2000-10-26 Cristales del acido (e)-4-[4-(5-metil-2-fenil-4-oxazolilmetoxi)benziloxiimino]-4-fenilbutirico

Country Status (18)

Country Link
US (1) US6777435B1 (es)
EP (1) EP1224178B1 (es)
KR (1) KR100433885B1 (es)
CN (1) CN1407975A (es)
AR (1) AR031078A1 (es)
AT (1) ATE243684T1 (es)
AU (1) AU7958100A (es)
CA (1) CA2388200A1 (es)
CL (1) CL2000002938A1 (es)
CO (1) CO5261530A1 (es)
DE (1) DE60003577T2 (es)
HU (1) HUP0203884A3 (es)
MY (1) MY135840A (es)
NO (1) NO20022007L (es)
PE (1) PE20010761A1 (es)
PL (1) PL364171A1 (es)
TW (1) TW558554B (es)
WO (1) WO2001032637A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1277730A4 (en) * 2000-03-28 2005-03-16 HEMMER OF NEOVASCULARIZATION
US20030045553A1 (en) 2001-04-04 2003-03-06 Bussolari Jacqueline C. Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
EP1392326B1 (en) * 2001-04-04 2009-09-09 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
CA2448741C (en) * 2001-05-30 2010-06-22 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
TWI327462B (en) * 2002-01-18 2010-07-21 Sumitomo Chemical Co Condensed heterocyclic sulfonyl urea compound, a herbicide containing the same, and a method for weed control using the same
US7556926B2 (en) 2002-05-24 2009-07-07 Takeda Pharmaceuticals Company Ltd. Methods for screening insulin-sensitizing agents
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
EP1791904B1 (en) * 2004-09-24 2014-08-27 University of Maryland, Baltimore Method of treating organophosphorous poisoning
JP2009507050A (ja) * 2005-09-08 2009-02-19 ガストロテック・ファルマ・アクティーゼルスカブ 胆道ジスキネジーおよび／または胆道痛／不快の治療のためのｇｌｐ−１分子の使用
TW201138843A (en) 2009-12-18 2011-11-16 Colgate Palmolive Co Biguanide preservation of precipitated calcium carbonate
US11191755B2 (en) 2014-01-17 2021-12-07 Cornell University Compositions and methods for providing cardioprotective effects
CA2937107C (en) 2014-01-17 2020-12-22 Cornell University Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
KR102281228B1 (ko) 2019-09-03 2021-07-22 신창수 과수나무의 가지지지용 파이프클램프

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9910371A (pt) 1998-05-11 2001-01-09 Takera Chemical Ind Ltd Composto, composição farmacêutica, agente para controlar os receptores relacionados com a retinóide, processos de prevenção e terapia da diabetes mellitus, de prevenção e terapia da hiperlipemia, para acentuar uma sensibilidade à insulina, para melhorar uma resistência à insulina, de prevenção e terapia da tolerância à glicose prejudicada, de prevenção e terapia de uma doença inflamatória, de prevenção de uma esclerose arterial, e, uso do composto
EP1227081A4 (en) * 1999-10-29 2004-08-11 Takeda Chemical Industries Ltd PROCESS FOR THE PREPARATION OF OXYMINOALKANOIC ACID DERIVATIVES

Also Published As

Publication number Publication date
HUP0203884A3 (en) 2005-01-28
KR20010102429A (ko) 2001-11-15
TW558554B (en) 2003-10-21
NO20022007D0 (no) 2002-04-26
CN1407975A (zh) 2003-04-02
HK1044536A1 (en) 2002-10-25
ATE243684T1 (de) 2003-07-15
NO20022007L (no) 2002-06-24
EP1224178A1 (en) 2002-07-24
PL364171A1 (en) 2004-12-13
US6777435B1 (en) 2004-08-17
DE60003577T2 (de) 2004-04-29
CA2388200A1 (en) 2001-05-21
DE60003577D1 (de) 2003-07-31
CO5261530A1 (es) 2003-03-31
AR031078A1 (es) 2003-09-10
HUP0203884A2 (hu) 2003-03-28
KR100433885B1 (ko) 2004-06-04
AU7958100A (en) 2001-05-14
MY135840A (en) 2008-07-31
WO2001032637A1 (en) 2001-05-10
CL2000002938A1 (es) 2009-05-15
EP1224178B1 (en) 2003-06-25

Similar Documents

Publication Publication Date Title
PE20010761A1 (es) Cristales del acido (e)-4-[4-(5-metil-2-fenil-4-oxazolilmetoxi)benziloxiimino]-4-fenilbutirico
PE20040704A1 (es) Monoetanosulfonato de 3-z-[1-(4-(n-((4-metil-piperazina-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metilen]-6-metoxicarbonil-2-indolinona y preparacion de medicamentos que los comprenden
CA2495943A1 (en) Indoles having anti-diabetic activity
NO20063431L (no) 3-(4-Benzyloksyfenyl)propionsyrederivater
PE20020637A1 (es) Derivados de 5-oxo-pirrolidina como agonistas de prostaglandinas
CO5150238A1 (es) Polimorfos de telmisartan, procedimiento para su preparacion y su empleo para la preparacion de un medicamento
DE69834028D1 (de) Zinkfreie insulinkristalle für die verwendung in medikamenten, die über die lunge verabreicht werden.
ES8604927A1 (es) Procedimiento para la preparacion de nuevos compuestos fluoroalcoxilicos
WO2004066963A3 (en) N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
ES2067637T3 (es) Procedimiento para producir una multicapa de membrana porosa de politetrafluoroetileno y estructura de multicapa de politetrafluoroetileno semisinterizada.
NZ535684A (en) Use of a GLP-1 (glucagon like peptide-1) compound to treat gastroparesis by increasing gastric emptying
AU641952B2 (en) Substituted N-(imidazolyl)alkyl alanine derivatives
IT1247331B (it) Dispositivo perforatore per nastri di carta o simili, con movimento alternativo di traslazione della contro-lama.
ES8505944A1 (es) Procedimiento para la preparacion de nuevas sulfonamidas.
DK364489A (da) Boreindretning til fremstilling af borehuller med en underskaering
ES2115673T3 (es) Derivados de acido 2-(3-(4-amidino-fenil))-propionico, su obtencion y empleo.
EP0082681A3 (en) Herbicidal sulfonamides
AR036054A1 (es) Uso de compuestos de aminoacetonitrilo para el control de plagas, una composicion y un proceso para dicho control y una composicion farmaceutica contra parasitos
NO20050511L (no) Skjaereapparat for ekstern ledning
DE50311252D1 (de) Benzylhemiformal enthaltende mikrobizide mittel
NO20034481D0 (no) Filmkombinasjon med minst to lag
AR009641A1 (es) Derivados de la 4-hidroxi-piperidina, su utilizacion, un procedimiento para prepararlos y medicamentos que los contienen.
AU4635189A (en) Process for the interconversion of two separate crystal forms of a herbicidal pyridine sulfonamide
WO2003089653A3 (en) Human il-18 crystal structure
AR042980A1 (es) Modificacion cristalina de la 2-(3,5-bis-trifluormetil-fenil)-n-[6-(1,1-dioxo-1lambda6-tiomorfolin-4-il)-4- (4-fluor-2-metil-fenil)-piridin-3-il]-n-metil-isobutiramida

Legal Events

Date Code Title Description
FD Application declared void or lapsed